Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies,OncoImmunology

当前位置： X-MOL 学术 › Oncoimmunology › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
OncoImmunology ( IF 7.2 ) Pub Date : 2023-10-04 , DOI: 10.1080/2162402x.2023.2261248
Tuba N Gide _{1,

2,

3} , Elizabeth C Paver _{1,

4} , Zarwa Yaseen _{1,

2} , Nigel Maher _{1,

3,

4,

5} , Nurudeen Adegoke _{1,

2,

3} , Alexander M Menzies _{1,

3,

6,

7} , Ines Pires da Silva _{1,

2,

3,

8} , James S Wilmott _{1,

2,

3} , Georgina V Long _{1,

2,

3,

6,

7} , Richard A Scolyer _{1,

2,

3,

4,

5}

Affiliation

Lymphocyte-activation gene-3 (LAG-3), an immune checkpoint receptor, negatively regulates T-cell function and facilitates immune escape of tumors. Dual inhibition of LAG-3 and programmed cell death...

中文翻译：